Precision Optics Announces Receipt of $3.5 Million Follow-On Production Order for Single-Use Ophthalmic Program
Rhea-AI Summary
Precision Optics (NASDAQ: POCI) received a follow-on production order of approximately $3.5 million for a single-use ophthalmic endoscope. Shipments are expected to commence shortly and be fulfilled over 12–15 months, supporting the customer’s transition from limited launch to full launch.
The program is Precision Optics’ second single-use design to enter production and follows an initial production order announced in November 2024. Management cites multi-year development and IP investments as enabling the shift to single-use endoscopy.
Positive
- $3.5M follow-on production order
- Shipments scheduled over 12–15 months
- Second single-use program moved into production
- Multi-year R&D and IP investments validated
Negative
- Order appears concentrated with a single large customer
- Revenue recognition spread over 12–15 months may delay cash flow
News Market Reaction – POCI
In the May 5 session, POCI gained 8.75%, reflecting a notable positive market reaction. Argus tracked a peak move of +10.0% during that session. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. Trading volume was elevated at 2.1x the daily average, suggesting notable buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 27 | Equity offering priced | Negative | -0.5% | Upsized $10M public offering at $3.60 per share with over-allotment. |
| Mar 26 | Equity offering proposed | Negative | -0.5% | Announcement of underwritten public offering under existing shelf registration. |
| Feb 17 | Q2 2026 earnings | Neutral | -0.6% | Record $7.37M revenue with strong growth but weak 2.8% gross margin and losses. |
| Feb 13 | Earnings call notice | Neutral | -5.7% | Scheduling of Q2 FY2026 conference call and 10-Q filing timing. |
| Nov 13 | Q1 2026 earnings | Positive | -10.5% | Record $6.68M revenue and >25M FY revenue outlook despite margin compression. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Equity offerings and even positive earnings/guidance have often been followed by negative price reactions.
Over the past six months, Precision Optics has combined rapid growth with capital raises. Q1 FY2026 revenue reached a record $6.68M and Q2 climbed to $7.37M, though gross margins contracted sharply and losses persisted. In March 2026, the company launched and priced an upsized $10M underwritten offering at $3.60 per share under an effective shelf, alongside related 8‑K and 424B5 filings. Historically, shares have often traded lower following both offerings and earnings updates, framing how investors might contextualize this new $3.5M production order.
Key Terms
single-use ophthalmic endoscope medical
single-use endoscopy medical
endoscope-based system medical
intellectual property technical
digital imaging solutions technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Order supports customer’s full launch, with shipments expected to commence shortly and be fulfilled over 12 -15 months
LITTLETON, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced the receipt of a follow-on production order totaling approximately
The single-use ophthalmic program is Precision Optics’ second single-use program to move into production, further highlighting the Company’s growth opportunity in single-use endoscopy. Shipments under the order are expected to commence shortly and be fulfilled over the following 12 to 15 months. The order, a follow-on from the initial production order announced in November 2024, is intended to support the customers’ ongoing limited launch and transition to full launch of the product.
“We are thrilled to receive this meaningful follow-on production order for our single-use ophthalmic program as our customer progresses toward full launch,” commented Dr. Joe Forkey, CEO of Precision Optics. “This program is the result of more than five years of joint product development and represents an important opportunity for both Precision Optics and our customer. The size of this follow-on order reflects the natural evolution of this program from initial stocking quantities to a sustained production phase.”
Dr. Forkey continued, “This version is designed to replace our customer’s current reusable endoscope-based system, which has been on the market for more than ten years. With the benefits of significantly improved image quality, combined with single-use functionality, we share our customer’s optimism this program has the potential to both replace their existing installed-base and increase their market share in the ophthalmic market.”
Precision Optics has invested over a period of years to develop the technology, intellectual property and production expertise required to support the market shift toward single-use endoscopy. The Company believes the transition of multiple single-use programs into production validates these investments and strengthens Precision Optics’ position as a partner of choice for medical device companies seeking advanced micro-optical and digital imaging solutions.
About Precision Optics Corporation
Founded in 1982, Precision Optics is a vertically integrated optics company primarily focused on leveraging its proprietary micro-optics, 3D imaging and digital imaging technologies to the healthcare and defense/aerospace industries by providing services ranging from new product concept through mass manufacture. Utilizing its leading-edge in-house design, prototype, regulatory and fabrication capabilities as well as its Ross Optical division's high volume worldwide sourcing, inspecting and production resources, the Company is able to design and manufacture next-generation product solutions to the most challenging customer requirements. Within healthcare, Precision Optics enables next generation medical device companies around the world to meet the increasing demands of the surgical community who require more enhanced and smaller imaging systems for minimally invasive surgery as well as 3D endoscopy systems to support the rapid proliferation of surgical robotic systems. In addition to these next generation applications, Precision Optics has supplied top-tier medical device companies with a wide variety of optical products for decades, including complex endocouplers and specialized endoscopes. The Company is also leveraging its technical proficiency in micro-optics to enable leading edge defense/aerospace applications which require the highest quality standards and the optimization of size, weight and power. For more information, please visit www.poci.com.
About Forward-Looking Statements
This press release contains forward-looking statements within the meaning of U.S. federal securities laws. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In addition, any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "would" and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. The forward-looking statements contained in this press release are based on certain assumptions and analyses made by the management of the Company in light of their respective experience and perception of historical trends, current conditions, and expected future developments and their potential effects on the Company as well as other factors they believe are appropriate in the circumstances. There can be no assurance that future developments affecting the Company will be those anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the control of the parties), or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, including risks that the closing conditions for this offering will not be achieved, the demand for the Company's products, global supply chains and economic activity in general and other risks and uncertainties identified in the Company's filings with the SEC. Should one or more of these risks or uncertainties materialize or should any of the assumptions being made prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities laws.
Company Contact:
PRECISION OPTICS CORPORATION
550 King Street, Bldg. A, Suite 100
Littleton, Massachusetts 01460
Telephone: 978-630-1800
Investor Contact:
LYTHAM PARTNERS, LLC
Robert Blum
Telephone: 602-889-9700
poci@lythampartners.com
